Psoriasis Clinical Trial
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.
Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis
Women must not be pregnant, lactating, or breastfeeding
Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 291 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.